As we've reported from other recent interventional cardiology conferences, the big news at this year's Transcatheter Cardiovascular Therapeutics (TCT) conference, held in Washington in September, was all about drug-eluting stents (DES), though as much for their practical application as their clinical success. During the first three days, interventional cardiologists and device company executives packed rooms where presenters promised insights into real-world experience with stents, followed the last two days by a DES Summit. All told, the data on cost analyses easily rivaled clinical trials' figures on technical efficacy as attention-grabbing indicators of potential impact on adoption rates.
The biggest news at this year's meeting was, as anticipated, Boston Scientific Corp. 's release on the first day...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?